Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

Overview of attention for article published in Lancet Oncology, December 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 2 news outlets
policy: 2 policy sources
twitter: 9 X users

patent: 2 patents
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 163 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 84,398 followers.

[Articles] Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label,... http://t.co/vZBvhtDG

http://t.co/CONW2yUz MAPK inhibitor Selumetenib in ovarian cancer

RT @cancermedmda: Chemoresistant low-grade serous #ovariancancer responds to MAPK inhibitors, Lancet Oncology http://t.co/qHAUTmCr #biotech

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.